Patient Education Leaflet

What's produced

A print-ready, compliant patient information document.

Every Patient Education Leaflet produced by Spectrum& is a complete, print-ready 6–12 page A4 PDF. The document includes all mandatory ABPI elements: product information correct at time of printing, Yellow Card adverse event reporting statement, the relevant job bag reference and date of preparation, and Vancouver-referenced clinical citations where evidence is cited.

Medi writes the clinical copy from source — directly from the approved SmPC and peer-reviewed literature sourced by Aria. Readability is scored throughout the writing process using Flesch-Kincaid. Every section targeting patients must score 8 or below. Medical terminology is explained in plain language without removing clinical accuracy.

Viz produces the full A4 page designs, applying your brand visuals and ensuring mandatory statements are correctly positioned and sized. Reg reviews the completed document against ABPI 2024 before delivery, and the MLR reference pack is included automatically.

The team

The team behind it.

Core team shown. Complexity tier determines which additional specialists are activated.

Complexity tiers

Simple, Medium, or Complex — you choose the depth.

	Simple	Medium	Complex
Scope	6pp · single indication	6–8pp · evidence section + FAQs	8–12pp · multi-indication · subgroup tailoring
Team	Sys, Medi, Reg, Viz, Pace	+ Aria	+ Ink
Price range	~£280	~£520	~£1,100
Best for	Standard product launch leaflet, single indication	Evidence-rich chronic condition, engaged patient audience	Multi-indication biologic, complex dosing, subgroup guidance

Example output

What it looks like.

Verixtol® — Patient Information Leaflet (Simple)

Understanding Verixtol® (verixtumab 150mg)

This leaflet gives you important information about Verixtol® (verixtumab 150mg). Please read it carefully before you start your treatment. Keep this leaflet — you may need to read it again.

What is Verixtol?

Verixtol is a medicine used in adults to treat moderate-to-severe plaque psoriasis — a skin condition that causes red, scaly patches. It works by targeting a protein in your immune system called interleukin-17A, which plays a key role in causing the inflammation that leads to psoriasis symptoms.

How to take Verixtol

Verixtol is given as an injection under the skin (subcutaneous injection). Your healthcare team will train you or a carer to give the injections at home. The usual starting dose is 150mg, given once a week for five weeks, followed by 150mg once a month.

Important safety information

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Hartwell Pharmaceuticals Medical Information.

Verixtol® — Patient Information Leaflet (Medium)

Understanding Verixtol® (verixtumab 150mg)

This leaflet contains detailed information about Verixtol, including how clinical trials show it works, answers to commonly asked questions, and guidance on managing your treatment at home.

What the evidence shows

In the VERIFY-1 clinical trial, 72% of adults treated with Verixtol 150mg achieved clear or almost clear skin after 16 weeks of treatment, compared to 4% in the placebo group.¹ Most people noticed improvement in their symptoms within the first four weeks.

72%

of patients achieved clear or almost clear skin at week 16 (VERIFY-1, n=312)¹

Frequently asked questions

Can I drink alcohol while taking Verixtol? There are no known interactions between Verixtol and alcohol. However, alcohol can affect your immune system, so your healthcare team may advise limiting your intake.

1. Hartwell Pharmaceuticals. VERIFY-1 Clinical Study Report. 2025.

Verixtol® — Patient Information Leaflet (Complex)

Verixtol® for Axial Spondyloarthritis & Plaque Psoriasis

This comprehensive leaflet covers both licensed indications for Verixtol, with guidance tailored to your specific diagnosis and treatment plan. Please use the contents guide to navigate to the section most relevant to you.

Section 2: Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is an inflammatory condition affecting the joints of the spine and pelvis. Verixtol is approved for adults with active axSpA who have responded inadequately to conventional therapy.

58%

of axSpA patients achieved ASAS40 response at week 16 vs 17% placebo (VERIFY-AXIA, n=341)²

Subgroup information: patients with IBD history

If you have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis), you should discuss this with your specialist before starting Verixtol. Medicines in the same class have been associated with new or worsening IBD symptoms in a small number of patients.

2. Hartwell Pharmaceuticals. VERIFY-AXIA Clinical Study Report. 2025.

Full rendered examples will be available at launch.

ABPI 2024 Compliance

This deliverable is subject to the ABPI 2024 Code of Practice. All materials include a full Reg compliance review, MLR reference pack, and mandatory statement audit before delivery.

Patient Education Leaflet.
Written for the patient who needs to understand their treatment.

A print-ready, compliant patient information document.

The team behind it.

Simple, Medium, or Complex — you choose the depth.

What it looks like.

ABPI 2024 Compliance

Start your Patient Leaflet.

Patient Education Leaflet.Written for the patient who needs to understand their treatment.

A print-ready, compliant patient information document.

The team behind it.

Simple, Medium, or Complex — you choose the depth.

What it looks like.

ABPI 2024 Compliance

Start your Patient Leaflet.

Patient Education Leaflet.
Written for the patient who needs to understand their treatment.